Gonadotropin-releasing hormone (GnRH) receptor agonists or antagonists given as androgen deprivation therapy (ADT) are a standard of care in advanced prostate cancer treatment [1,2,3,4,5,6,7]. This evidence concerns the gene GNRHR and Familial prostate cancer.